The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
Scope
This report gives an important monthly update on the pharmaceutical outsourcing industry, based on analysis from the analyst's experts and our databases covering deals, companies, drugs, financials, news, clinical trials, and more. This report is required reading for:- CMO executives and strategic decision-makers: to improve understanding of the CMO industry and provide a critical input for strategic planning efforts.
- Sourcing and procurement executives in bio/pharmaceutical companies: to improve understanding of crucial components of the supply base that will provide insights for supplier selection and management.
- Investors, advisors, and consultants: they can gain a deeper understanding of the CMO market and important insights for identifying potential investment targets.
Reasons to Buy
- Understand current trends and equip yourself with forward-thinking strategies to navigate challenges and capitalise on emerging trends driving the pharmaceutical manufacturing industry. Use our radar to identify developments and innovations with high impact.
- Discover the latest opportunities and threats in the contract manufacturing industry, based on clinical trials and regulatory decisions.
- Learn about the past quarter’s M&A and financing deals in the manufacturing space.
- Identify the latest contract service agreements.
- Develop your competitor or market intelligence by reading about inspection outcomes and facility investments.
- Stay ahead of disruption with updates on supply chain obstacles and new regulations.
Table of Contents
1 Industry Trends
2 Industry Analysis
3 Value Chain
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AAVantgarde Bio Srl
- Ablynx
- AGC Biologics Inc
- Almac Group Ltd
- Amgen Ltd
- Angelini Pharma SpA
- Argenx SE
- Aspen Pharmacare Holdings Ltd
- AstraZeneca Pharmaceuticals LP
- Bachem Holding AG
- Bayer AG
- BioAge Labs
- BioNTech
- BioOra Ltd
- Borealis
- Bora Pharmaceuticals Co Ltd
- Brewcrispr
- Bristol Myers Squibb
- Cambrex Corp
- Capital Bio
- Catalent Inc
- Charles River Laboratories International Inc
- Chemspec-API Inc
- Chiesi Farmaceutici SpA
- Curevac
- Deciphera Pharmaceuticals Inc
- Delpharm SAS
- Eli Lilly
- Eurofins Scientific SE
- Forge Biologics Inc
- Gan & Lee Pharmaceuticals Co Ltd
- GSK plc
- Genezen Laboratories Inc
- Glaxo Group Ltd
- Ionis Pharmaceuticals Inc
- Janssen Biotech Inc
- Juzen Chemical Corp
- Latina Pharma SpA
- Lek Pharmaceuticals
- Lonza Group Ltd
- Lonza Biologics Inc
- Lubrizol Life Science Health
- MacroGenics Inc
- Merck & Co Inc
- Merck Sharp & Dohme (UK) Ltd
- MilliporeSigma
- Mirum Pharmaceuticals Inc
- Miltenyi Biotec BV & Co KG
- Novartis Pharmaceuticals Corp
- Novartis Pharmaceuticals UK Ltd
- Organon & Co
- Pfizer
- Provention Bio Inc
- Regeneron Pharmaceuticals Inc
- Rentschler Biopharma
- Roche
- Rubicon Research Ltd
- Sanofi
- Sciarra Laboratories Inc
- Siolta Therapeutics
- Simtra US LLC
- Swedish Orphan Biovitrum Ltd
- Tiziana Life Sciences Ltd
- Transcode Therapeutics Inc
- Vetter Pharma-Fertigung GmbH & Co KG
- Verismo Therapeutics Inc
- Viralgen Vector Core SL
- X4 Pharmaceuticals Inc
- Zhejiang Raybow Pharmaceutical Co Ltd
